General Principles of Pharmacologic Therapy

Psychiatry: Third Edition

Volumn 2, Issue , 2008, Pages 2097-2111

  Ismail, Zahinoor ^a   Pollock, Bruce G ^a   Roose, Steven P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Adverse drug reactions; Drug interactions; Efficacy; Exposure; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Safety

Indexed keywords

EID: 84889797561     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470515167.ch99     Document Type: Chapter

References (79)

1. Addington D The Calgary Depression Scale for Schizophrenia; http://www.ucalgary.ca/cdss/.
2. Aparasu RR, Mort JR, Brandt H, et al. (2003) Psychotropic prescription use by community-dwelling elderly in the United States. Journal of The American Geriatrics Society 51(5), 671-677.
3. Baciu A, Stratton K, Burke S, et al. (eds) (2006) The Future of Drug Safety: Promotin Gand Protecting the Health of the Public. National Academies Press, Washington, DC, USA.
4. Basile VS, Masellis M, Badri F, et al. (1999) Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsycho pharmacology 21(1), 17-27.
5. Beaufrere B and Morio B (2000) Fat and protein redistribution with aging: Metabolic considerations. European Journal of Clinical Nutrition 54 (Suppl 3), S48-S53.
6. Bebia Z, Buch SC, Wilson JW, et al. (2004) Bioequivalence revisited: Influence of age and sex of CYP enzymes. Clinical Pharmacology and Therapeutics 76(6), 618-62.
7. Beck CA, Williams JV, Wang JL, et al. (2005) Psychotropic medication use in Canada. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 50(10), 605-613.
8. Benedetti F, Mayberg HS, Wager TD, et al. (2005) Neurobiological mechanisms of the placebo effect. Journal of Neuroscience 25(45), 10390-10402.
9. Benet LZ and Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clinical Pharmacology and Therapeutics 71(3), 115-121.
10. Benet LZ, Izumi T, Zhang Y, et al. (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. Journal of Controlled Release 62(1-2), 25-31.
11. Bengtsson F (2004) Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Therapeutic Drug Monitoring 26(2), 145-151.
12. Bies RR, Feng Y, Lotrich FE, et al. (2004) Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. Journal of Clinical Pharmacology 44(12), 1352-1359.
13. Bigos KL, Bies RR, Pollock BG, et al. (2006) Population pharmacokinetics in geriatric psychiatry. American Journal of Geriatric Psychiatry 14(12), 993-1003.
14. Blesa R, Bullock R, He Y, et al. (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenetics and Genomics 16(11), 771-774.
15. Burton PS, Goodwin JT, Vidmar TJ, et al. (2002) Predicting drug absorption: How nature made it a difficult problem. Journal of Pharmacology and Experimental Therapeutics 303(3), 889-895.
16. Carnahan RM, Lund BC, Perry PJ, et al. (2002) A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice. Psychopharmacology Bulletin 36(2), 24-39.
17. Carnahan RM, Lund BC, et al. (2006) The anticholinergic drug scale as a measure of drug-related anticholinergic burden: Associations with serum anticholinergic activity. Journal of Clinical Pharmacology 46(12), 1481-1486.
18. Cockroft D and Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
19. Doherty MM and Charman WN (2002) The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism? Clinical Pharmacokinetics 41(4), 235-253.
20. Dresser GK, Spence JD, Bailey DG, et al. (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 38(1), 41-57.
21. Ette EI and Williams PJ (2004) Population pharmacokinetics I: Background, concepts, and models. Annals of Pharmacotherapy 38(10), 1702-1706.
22. FDA (2007) FDA's Commitment to Drug Safety Fact Sheet; http://www.fda.gov/oc/factsheets/drugsafety-iom.html
23. Feng Y, Pollock BG, Ferrell RE, et al. (2006) Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. British Journal of Clinical Pharmacology 61(5), 558-569.
24. Flockhart D Drug-Interactions. com ; http://medicine.iupui.edu/flockhart/.
25. Frye RF, Zgheib NK, Matzke GR, et al. (2006) Liver disease selectively modulates cytochrome P450-mediated metabolism. Clinical Pharmacology and Therapeutics 80(3), 235-245.
26. Gibaldi M and Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, USA.
27. Grant DM (1999) Pharmacogenomics and the changing face of clinical pharmacology. The Canadian Journal of Clinical Pharmacology 6(3), 131-132.
28. Greenblatt DJ and Harmatz JS (1993) Kinetic-dynamic modeling in clinical psychopharmacology. Journal of Clinical Psychopharmacology 13(4), 231-234.
29. GreenblattDJ, Harmatz JS, Shader RI, etal. (1991) Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clinical Pharmacokinetics 21(3), 165-177.
30. Gunes A, Scordo MG, Spina E, et al. (2007) Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 190(4), 479-484.
31. Guzey C, Scordo MG, Spina E, et al. (2007) Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology 63(3), 233-241.
32. Harter JG and Peck CC (1991) Chronobiology. Suggestions for integrating it into drug development. Annals of The New York Academy Of Sciences 618, 563-571.
33. Iber FL, Murphy PA, Connor ES, et al. (1994) Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs and Aging 5(1), 34-48.
34. Ingelman-Sundberg M, Daly A, Nebert D, et al. (Date accessed March 2007) Human Cytochrome P450 (CYP) Allele Nomenclature Committee; http://www.imm.ki.se/CYPalleles
35. Ingelman-Sundberg M, Oscarson M and McLellan RA, (1999) Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends in Pharmacological Sciences 20(8), 342-349.
36. Insel TR and Scolnick EM (2006) Cure therapeutics and strategic prevention: Raising the bar for mental health research. Molecular Psychiatry 11(1), 11-17.
37. Kalow W, Goedde W, and Agarwal D, (1986) Ethnic Differences in Reactions to Drugs and Xenobiotics. Alan R Liss, New York, USA.
38. Khan A, Schwartz K, Redding N, et al. (2007) Psychiatric Diagnosis and Clinical Trial Completion Rates: Analysis of the FDA SBA Reports. Neuropsychopharmacology.
39. Kirby D and Ames D (2001) Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. International Journal of Geriatric Psychiatry 16(5), 484-493.
40. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. (1992) Identification of rifampin-inducible P4501IIA4 (CYP3A4) in human small bowel enterocytes. Journal of Clinical Investigation 90(5), 1871-1878.
41. Laroche ML, Charmes JP, Nouaille Y, et al. (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? British Journal of Clinical Pharmacology 63(2), 177-186.
42. Leape LL and Berwick DM (2005) Five years after to err is human: What have we learned? JAMA: The Journal of The American Medical Association 293(19), 2384-2390.
43. Levine R and Fink M (2006) The case against evidence-based principles in psychiatry. Medical Hypotheses 67(2), 401-410.
44. Lewis DA and Gonzalez-Burgos G (2006) Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine 12(9), 1016-1022.
45. Lieberman JA, Stroup TS, McEvoy JP, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353(12), 1209-1223.
46. Lotrich FE, Bies RR, Smith GS, et al. (2006) Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. Journal of Psychopharmacology 20 (4 Suppl), 33-40.
47. Lotrich FE and Pollock BG (2005) Aging and clinical pharmacology: Implications for antidepressants. Journal of Clinical Pharmacology 45(10), 1106-1122.
48. McLean AJ and Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacological Reviews 56(2), 163-184.
49. Mulsant BH, Houck PR, Gildengers AG, et al. (2006) What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? Journal of Clinical Psychopharmacology 26(2), 113-120.
50. Nemeroff CB, DeVane CL, Pollock BG, et al. (1996) Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 153(3), 311-320.
51. Ohlsen RI and Pilowsky LS (2005) The place of partial agonism in psychiatry: Recent developments. Journal of Psychopharmacology 19(4), 408-413.
52. Oliveria SA, Liperoti R, L'ltalien G, et al. (2006) Adverse events among nursing home residents with Alzheimer's disease and psychosis. Pharmacoepidemiology and Drug Safety 15(11), 763-774.
53. Pakulski C, Drobnik L, Millo B, et al. (2000) Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Medical Science Monitor 6(2), 314-318.
54. Peck CC (2003) Postmarketing drug dosage changes. Pharmacoepidemiology and Drug Safety 12(5), 425-426.
55. Phillips J, Beam S, Brinker A, et al. (2001) Retrospective analysis of mortalities associated with medication errors. American Journal of Health-System Pharmacy 58(19), 1835-1841.
56. Pollock BG (1999) Adverse reactions of antidepressants in elderly patients. Journal of Clinical Psychiatry 60 (Suppl 20), 4-8.
57. Pollock BG, Everett G, Perel JM, et al. (1992a) Comparative cardiotoxicity of nortriptyline and its isomeric 10-hydroxymetabolites.Neuropsychopharmacology 6(1), 1-10.
58. Pollock BG, Laghrissi-Thode F, et al. (2000) Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology 20(2), 137-140.
59. Pollock BG, Mulsant BH, et al. (1995) Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacology Bulletin 31(2), 327-331.
60. Pollock BG, Perel JM, et al. (1992b) Debrisoquine hydroxylationphenotyping in geriatric psychopharmacology.Psychopharmacology Bulletin 28(2), 163-168.
61. Preskorn SH (2006) Pharmacogenomics, informatics, and individual drug therapy in psychiatry: Past, present and future. Journal of Psychopharmacology 20 (4 Suppl), 85-94.
62. Reuben D, Herr K, Pacala J, et al. (2006) Geriatrics at Your Fingertips: 2006-2007. The American Geriatrics Society, New York, USA.
63. Richards JB, Papaioannou A, Adachi JD, et al. (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Archives of Internal Medicine 167(2), 188-194.
64. Ronfeld RA, Tremaine LM, Wilner KD, et al. (1997) Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clinical Pharmacokinetics 32 (Suppl 1), 22-30.
65. Roose SP and Schatzberg AF (2005) The efficacy of antidepressants in the treatment of late-life depression. Journal of Clinical Psychopharmacology 25 (4 Suppl 1), S1-S7.
66. Rush AJ, Fava M, Wisniewski SR, et al. (2004) Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Controlled Clinical Trials 25 (1), 119-142.
67. Sachs GS, Thase ME, Otto MW, et al. (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biological Psychiatry 53 (11), 1028-1042.
68. Sasongko L, Link JM, Muzi M, et al. (2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics 77(6), 503-514.
69. Schmucker DL (2001) Liver function and phase I drug metabolism in the elderly: A paradox. Drugs and Aging 18(11), 837-851.
70. Snowdon J, Day S, Baker W, et al. (2006) Current use of psychotropic medication in nursing homes. International Psychogeriatrics 18(2), 241-250.
71. Steinmetz KL, Coley KC, Pollock BG, et al. (2005) Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. Journal of the American Geriatrics Society 53(5), 891-894.
72. Thomas CP, Conrad P, Casler R, et al. (2006) Trends in the use of psychotropic medications among adolescents, 1994 to 2001. Psychiatric Services 57(1), 63-69.
73. Timmer CJ, Paanakker JE, Vrijmoed-de Vries M, et al. (1997) Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations. Pharmaceutical Research 14(1), 98-102.
74. Tune LE (2000) Serum anticholinergic activity levels and delirium in the elderly. Seminars in Clinical Neuropsychiatry 5(2), 149-153.
75. Urquhart J (2004) Getting a handle on why good drugs sometimes don't work. The Journal of the Royal College of Physicians of Edinburgh 34.
76. Walsh BT, Seidman SN, Sysko R, et al. (2002) Placebo response in studies of major depression: Variable, substantial, and growing. JAMA: The Journal of the American Medical Association 287(14), 1840-1847.
77. Weiden PJ, Kozma C, Grogg A, et al. (2004) Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services 55(8), 886-891.
78. Whyte EM, Romkes M, Mulsant BH, et al. (2006) CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. International Journal of Geriatric Psychiatry 21(6), 542-549.
79. Wynne HA, Goudevenos J, Rawlins MD, et al. (1990) Hepatic drug clearance: The effect of age using indocyanine green as a model compound. British Journal of Clinical Pharmacology 30(4), 634-637.